Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of anti-human immunodeficiency virus (HIV) drug amprenavir in preparation of antitumor drug

A tumor and drug technology, applied in the field of medicine, can solve the problem that the inhibitory effect has not been reported, and achieve the effect of shortening the research and development cycle, inhibiting the proliferation of tumor cells, and reducing the research and development investment.

Inactive Publication Date: 2014-01-29
SICHUAN UNIV
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the inhibitory effect of enprenavir on breast cancer, non-small cell lung cancer, colon cancer, glioma, and fibroblastoma has not been reported yet.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of anti-human immunodeficiency virus (HIV) drug amprenavir in preparation of antitumor drug
  • Application of anti-human immunodeficiency virus (HIV) drug amprenavir in preparation of antitumor drug
  • Application of anti-human immunodeficiency virus (HIV) drug amprenavir in preparation of antitumor drug

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Embodiment 1: Preparation of amprenavir stock solution

[0043] Amprenavir (CAS No.161814-49-9, purity>98%) was purchased from Shanghai Hanxiang Biotechnology Co., Ltd. Drugs were first dissolved in DMSO to make a concentration of 10 -2 Stock solution of M, aliquoted, stored at -80°C

Embodiment 2

[0044] Embodiment 2: the culture of tumor cell

[0045] 1. Materials and methods

[0046] 1.1 Materials

[0047] Strains: breast cancer MCF-7 cells, non-small cell lung cancer A549 cells, mouse fibroblastoma L929 cells, colon cancer HT29 cells, glioma U87 cells (purchased from the cell bank of Shanghai Institute of Biological Sciences)

[0048] Medium: RPMI-1640 medium (100 M / mL penicillin + 100 M / mL streptomycin) supplemented with 10% (v / v) calf serum

[0049] 1.2 Method

[0050] (1) Cells were grown in suspension in RPMI-1640 medium (100 M / mL penicillin + 100 M / mL streptomycin) containing 10% calf serum, at 37°C, saturated humidity, 5% CO 2 cultured in an incubator.

[0051] (2) Change the culture medium once every 2-3 days.

[0052] (3) Collect the cells in the logarithmic growth phase for experiments.

Embodiment 3

[0053] Example 3: Inhibitory effect of Amprenavir on tumor cell proliferation

[0054] 1. Materials and methods

[0055] 1.1 Materials

[0056] 50 μM, 100 μM, 150 μM, 200 μM amprenavir solution: use the amprenavir stock solution obtained in Example 1 for dilution.

[0057] Breast cancer MCF-7 cells in logarithmic phase, non-small cell lung cancer A549 cells, mouse fibroblastoma L929 cells, colon cancer HT29 cells, and brain glioma U87 cells: obtained by the method described in Example 2.

[0058] 1.2 Method

[0059] (1) with 5×10 4 cells / mL, the tumor cells were inoculated in a 96-well plate, 100 μL of cell suspension per well (3 replicate wells for each group), and cultured for 24 hours.

[0060] (2) Using the RPMI-1640 culture medium without cells as the blank control group, add amprenavir at the final concentrations of 50, 100, 150, and 200 μM to the cultured cells, and culture them for 24h and 48h respectively.

[0061] (3) After adding 10 μL, 5 mg / mL MTT to each we...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of anti-human immunodeficiency virus (HIV) drug amprenavir in preparation of an antitumor drug. The anti-HIV drug amprenavir identified by food and drug administration (FDA) is taken as a material; the killing effect of the amprenavir on a tumor cell is detected by adopting a microwave theory and techniques (MTT) method. An experiment proves that the amprenavir has a significant inhibiting effect on multiplication of a plurality of tumor cells, such as a breast cancer michigan cancer foundation (MCF-7) cell, a non-small cell lung cancer A549 cell, a mouse embryonic fibroblast glioblastoma multiforme L929 cell, a colon cancer HT29 cell, a brain glioma U87 cell and the like, so as to clarify new use of an old drug. Therefore, foundation is provided for development of a novel anti-tumor drug.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to the application of amprenavir, an anti-HIV protease inhibitor drug, in anti-tumor. Background technique [0002] Since the 1970s, the concept of "one drug, one target, one disease" has been the main principle followed by drug discovery [1] . Although this concept has accelerated the pace of drug discovery and achieved outstanding results in the past few decades, its poor efficacy and high toxicity and side effects have also greatly increased the attrition rate of the drug discovery process, thus highlighting the The limitations of research and development ideas have exacerbated the difficulties faced by new drug research and development. Drugs may have multiple targets of action, a growing body of research suggests [2,3] , new targets for FDA-approved drugs have also been successfully predicted [4] . Considering the long discovery cycle and high investment of ne...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/635A61P35/00
Inventor 鲍锦库李鑫吴传芳李春漾孙荣王海莲卢帮敏李晓雨张彬
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com